Cytogenetic Effects of LSD 25 Therapy in Man
JAMA December 2, 1968 Peer reviewed DOI: 10.1001/jama.1968.03150100037008 via OpenAlex
Summary
Chromosome analysis in leukocytes from four patients undergoing experimental therapy with lysergic acid diethylamide (LSD) revealed that while aberration frequencies increased after three intravenous doses, they returned to control levels within one to six months post-treatment. Initial aberration rates were similar to those of control subjects. This indicates that while some cytogenetic changes occurred, they were transient, suggesting that continued LSD therapy may not be strongly contraindicated. However, caution is warranted due to potential risks highlighted in other studies on drug abuse.
Abstract
Chromosomes have been studied in leukocytes cultured from patients undergoing experimental therapy with lysergic acid diethylamide (LSD 25). Aberration frequencies prior to therapy were established for three of the four patients; these were comparable to frequencies in control subjects. Following each of three doses given intravenously (usually 200μg per dose), each patient's chromosomes were reexamined. Some increase in aberration frequency was observed, along with the appearance of some types of aberration not present before treatment. However, a return to control levels occurred in follow-up samples taken one to six months after the final dose was administered. We feel therefore that continued experimental therapy is not strongly contraindicated. On the other hand, these results can not be construed to minimize the possible cytogenetic hazards suggested by other studies concerned primarily with drug abuse.